Novo Nordisk (NVO) Poised for 23.3% Upside as Obesity Market Expands and Clinical Trials Impress
We recently published a list of 10 Best Major Stocks to Invest In According to Analysts. In this article, we are going to ...
Is Novo Nordisk A/S (NYSE:NVO) The Top Global Stock To Buy Now?
With the third quarter of 2024 ending, the discourse on the stock market for global equities has shifted back to interest ...
Medscape4h
Popular Weight Loss Drugs Now for Patients With Cancer?
Some oncologists are turning to GLP-1 agents to help patients shed excess pounds, with the goal of improving cancer outcomes.
Opinion
The Columbian4hOpinion
Jarvis: High weight loss drug costs hurt
On Tuesday, congressional leaders spent two hours taking to task Novo Nordisk Chief Executive Officer Lars Fruergaard Jørgensen over the high price of the company’s diabetes and obesity drugs, Ozempic ...
U.S. Rep. Lloyd Doggett pushes for generic Wegovy, Ozempic to lessen costs
U.S. representative from Austin asks Health and Human Services secretary to push for generic licensing of semaglutide ...
Ozempic, Wegovy shortages create anxiety, hunt for alternatives
Some people have turned to compound pharmacies to replace drugs in short supply, but medical professionals warn of a new ...
Butler Eagle13h
Who’s really keeping Ozempic and Wegovy prices so high?
On Tuesday, congressional leaders spent two hours taking to task Novo Nordisk Chief Executive Officer Lars Fruergaard ...
Opinion
The Scranton Times-Tribune13hOpinion
Lisa Jarvis: Who’s really keeping Ozempic and Wegovy prices so high?
On Tuesday, congressional leaders spent two hours taking to task Novo Nordisk Chief Executive Officer Lars Fruergaard Jørgensen over the high price of the company’s diabetes and obesity drugs, Ozempic ...